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Electron transfer chainhosphorylation (OXPHOS) system in the mitochondrial inner membrane is an
intricate process in which many factors must interact. The OXPHOS system is composed of four respiratory
chain complexes, which are responsible for electron transport and generation of the proton gradient in the
mitochondrial intermembrane space, and of the ATP synthase that uses this proton gradient to produce ATP.
Mitochondrial human disorders are caused by dysfunction of the OXPHOS system, and many of them are
associated with altered assembly of one or more components of the OXPHOS system. The study of assembly
defects in patients has been useful in unraveling and/or gaining a complete understanding of the processes
by which these large multimeric complexes are formed. We review here current knowledge of the biogenesis
of OXPHOS complexes based on investigation of the corresponding disorders.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionOxidative phosphorylation (OXPHOS) is the metabolic process that
provides most of the energy usable by cells. OXPHOS couples two sets
of reactions, respiration and ATP synthesis. Respiration consists of the
sequential transfer of electrons extracted from nutrient compounds
through a chain of oxidoreductase reactions, eventually leading to
reduction of molecular oxygen to water. The oxidoreductase reactions
are carried out by respiratory chain complexes I (CI, NADH:ubiquinone
oxidoreductase, EC 1.6.5.3), II (CII, succinate:ubiquinone oxidoreduc-
tase, EC 1.3.5.1), III (CIII, ubiquinol:ferricytochrome c oxidoreductase,
EC 1.10.2.2), and IV (CIV, cytochrome c oxidoreductase, COX, EC
1.9.3.1). The energy liberated during respiration sustains the formation
of a proton gradient across the inner mitochondrial membrane that is
exploited by ATP synthase or respiratory chain complex V (CV, F1F0
ATPase, EC 3.6.3.14) to catalyze the condensation of ADP and inorganic
phosphate into ATP, the main energy currency of the cell.
From a structural standpoint, the entire respiratory chain is
contained in the inner membrane of mitochondria. From a genetic
standpoint, the OXPHOS system is unique as it takes contributionsl rights reserved.
ogenetics, Foundation IRCCS
126 Milano, Italy. Fax: +39 02
).from two physically and functionally separated genomes, the nuclear
genome and the mitochondrial genome (mitochondrial DNA, mtDNA).
Defects in the respiratory chain result in human mitochondrial
diseases characterized by a wide combination of clinical symptoms
and organ involvement [1–3]. Disorders of the OXPHOS system have
an incidence of 1 in 5000 live births [4,5], and onset can be at any age,
although severe presentations in children are common. Mitochondrial
disorders can be due to mutations in both mtDNA and nuclear genes
coding for: (1) respiratory chain subunits; (2) assembly factors; (3)
factors affecting the maintenance and expression of mtDNA; (4)
enzymes involved in the biosynthesis of nonprotein components of
the respiratory chain; and (5) proteins indirectly related to OXPHOS.
By deﬁnition, OXPHOS disorders are characterized by defects in the
activity of one or more respiratory chain complexes, but the under-
lying gene abnormality often remains unknown, so that a genetic
cause is today identiﬁable in approximately half of the cases.
Mammalian mitochondrial respiratory chain complexes contain a
number of subunits much larger than that of their bacterial counter-
parts. The additional protein subunits that piled up during evolution
are not essential to catalytic activity, but must play a role in the
assembly, stability, and functional control of the enzymes.
Adhering to the title of our review, we focus on those defects that
result in altered assembly. The latter can be compromised by
abnormalities in either structural subunits or chaperones/assembly
factors. Investigation of these defects has not only been useful in
understanding the molecular pathogenesis of several mitochondrial
Table 1
Online Mendelian Inheritance in Man (OMIM) reference numbers for complex I
deﬁciency
Clinical phenotype Mutated gene OMIM [25]
Complex I deﬁciency Various 252010
LHON Various 535000
Leigh syndrome Various 256000
MELAS Various 540000
mtDNA-encoded structural subunits MTND1 516000
MTND2 516001
MTND3 516002
MTND4 516003
MTND4L 516004
MTND5 516005
MTND6 516006
Nuclear DNA-encoded structural subunits NDUFV1 16105
NDUFV2 600532
NDUFS1 157655
NDUFS2 602985
NDUFS3 603846
NDUFS4 602694
NDUFS6 603848
NDUFS7 601825
NDUFS8 602141
NDUFA11 Ref. [32]
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aspects of respiratory chain biogenesis in a mammalian system.
Despite the substantial progress achieved in this ﬁeld in recent years,
there remains a lack of understanding of several aspects. For example,
we know that BCS1L and SURF1 are important factors in the assembly
of CIII and CIV, respectively, but we ignore the precise mechanism by
which they accomplish this task. Moreover, we do not know whether
the manifestations of their defects are the consequence of their role in
assembly or, rather, due to a multiplicity of functions, some of which
are still unknown. This possibility has been hypothesized for a number
of factors: for instance, defects of BCS1L, the only known CIII assembly
factor, have been associated with iron overload and multivisceral
failurewith normal CIII activity in some patients [6], whereas in others
the main abnormality is, as expected, a speciﬁc defect of CIII;
mutations in SURF1, an assembly factor of CIV, are lethal in humans
and ﬂies, but are associated with prolonged longevity and neuropro-
tection from calcium-induced neuronal excitotoxicity in knockout
mice [7]; SCO1 and SCO2, two other CIV assembly factors, are involved
in maintenance of cellular copper homeostasis [8], and SCO2 has been
proposed to act as a metabolic checkpoint in controlling glycolysis
versus respiration as the main energy provider of the cell. Further
complexity derives from the recent observation that individual
respiratory complexes agglomerate into gigantic supercomplexes [9].
1.1. Genetic and biochemical tools used to investigate OXPHOS system
assembly
Studies on the yeast Saccharomyces cerevisiae have led not only to
an understanding of the basic mechanisms underlying the processes
of assembly of complexes III, IV, and V, but also to the discovery of
many assembly factors, some of which have orthologs in humans.
Because CI is missing in S. cerevisiae, other organisms, such as Neur-
ospora crassa and Yarrowia lipolytica, or mammals, like Bos taurus,
have served as models for the study of CI structure and assembly. Blue
native gel electrophoresis (BNGE) is a fundamental technique used to
analyze the molecular steps required for the assembly of OXPHOS
complexes in different organisms and conditions, including human
disease [10–12]. For example, the identiﬁcation of CI subcomplexes in
patients has allowed investigators to identify consistent anomalous
patterns and relate them to speciﬁc genetic defects. Furthermore, the
study of subcomplexes in mutant cells, and in normal cells after
inhibition of mitochondrial protein synthesis, has led to the delinea-
tion of the current models for CI assembly in humans and the
reﬁnement of those for CIII, CIV, and CV.
Mutations in CII are exceptionally rare in humans and their
investigation has not contributed to the elucidation of the assembly
process for this complex. Therefore, the following discussion is limited
to current knowledge of disease-related defective assembly of CI, CIII,
CIV, and CV.
2. Complex I
Complex I (NADH:ubiquinone oxidoreductase) is the principal
entry point of electrons into the respiratory chain as it catalyzes the
electron transfer from NADH to ubiquinone. It is also the largest
complex in the OXPHOS system, with a molecular weight of ≈ 980kDa;
it is composed of 45 subunits, 7 of which are encoded by mtDNA ND
genes, and the remaining 38 by nuclear DNA genes [13–15]. The
subunit composition and topology of mammalian CI have been
intensively investigated on preparations from bovine heart [13,16–
19]. Likewise, the human nucleus-encoded subunits have been
identiﬁed by homology with bovine sequences [19]. This information
has been crucial in gaining insight into the structural and functional
consequences of CI deﬁciency in human disease [20]. Crystallization of
bovine CI has not yet been achieved, but its overall structure is known
from low-resolution three-dimensional electron microscopy [21,22].Mammalian CI has the shape of an ‘L’, being composed of two arms
perpendicular to each other: a hydrophobic arm, embedded in the
mitochondrial inner membrane, which contains the mtDNA-encoded
subunits, and a hydrophilic peripheral arm protruding into the matrix
(reviewed in Ref. [23]). These structures harbor three functional
modules, the subunit composition of which has been (partially)
determined by subfractionation experiments [19,23]: (1) the dehy-
drogenase module, responsible for the oxidation of NADH to NAD+,
includes, at a minimum, the NDUFV2, NDUFV1, and NDUFS1 subunits;
(2) the hydrogenase module, responsible for the electron transfer to
ubiquinone, includes, at a minimum, the NDUFS2, NDUFS3, NDUFS7,
and NDUFS8 subunits; (3) the proton translocation module, which
constitutes the bulk of the membrane arm, includes, at a minimum,
the sevenmtDNA-encoded ND subunits [24]. Its gigantic size, the large
number of different subunits, and the several prosthetic groups that
are part of the holoenzyme make the assembly of CI a very
complicated process, for which several details are still missing (for
an exhaustive review see Ref. [24]).
CI deﬁciency (for OMIM [25] reference numbers, see Table 1) is the
most common cause of mitochondrial disease in both children and
adults as it is involved in about one-third of all cases of faulty OXPHOS
[23,26,27]. Clinical presentations are extremely heterogeneous;
however, most of the infantile cases fall into six main clinical
phenotypes: Leigh syndrome, fatal infantile lactic acidosis (FILA),
neonatal cardiomyopathy, leukoencephalopathy, pure myopathy, and
combined hepatopathy and tubulopathy [26–29]. Several presenta-
tions cannot be assigned to any of these groups and are generically
deﬁned as mitochondrial encephalomyopathy with CI deﬁciency
[23,29].
Most CI defects remain undeﬁned at the genetic and molecular
levels. Given the complexity of the enzyme, a large number of yet
unknown nuclear proteins are likely involved in its biogenesis;
mutations in any of these factors may, in turn, lead to CI deﬁciency
and disease.
Pathogenic mutations can be detected in approximately 20–40% of
the cases, this variability being due to the prevalent patient population
(e.g., adults versus children), stringency of the biochemical screening,
and exhaustiveness of the genetic and molecular investigation.
Depending on which genome is affected, CI-associated mutations
can be divided into two groups: those affecting mtDNA-encoded ND
genes and those affecting CI-related nuclear genes.
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Pathogenic mutations have been reported in each of the seven
mtDNA-encoded ND genes (Table 1). Clinical presentations include
Leber hereditary optic neuropathy (LHON), Leigh syndrome, multi-
system disorders such as MELAS (mitochondrial encephalopathy with
lactic acidosis and strokelike episodes), or MELAS/LHON overlap
syndromes. Onset may occur in infancy, but more often is in late
childhood or early adulthood [23,29–32].
Structural studies on speciﬁc ND mutations have shed some light
on the role of the corresponding subunits for the assembly/stability of
the complex. For instance, ND1, ND4, and ND6 are essential for the
assembly of CI, as their mutations are associated with markedly
reduced levels of the enzyme [31–38]. Mutations in ND2 alter
assembly with the accumulation of CI intermediates [39,40]. The
mutations reported in ND3 and ND5 did affect enzymatic activity but
were not essential for the assembly of CI [30,31,41,42].
2.2. Nuclear structural gene mutations
Mutations in nuclear-encoded genes [27,43] are usually associated
with severe clinical presentations, the onset being in the neonatal
period, infancy, or early childhood [23]. Mutations may affect nuclear-
encoded structural subunits of CI (Table 1), but also CI assembly factors.
The latter group is much smaller, comprising mutations in only three
genes: B17.2L or NDUFA12L (bovine and human nomenclature,
respectively) [44,45], CIA30 (named NDUFAF1 in humans [46]), and
C6ORF66 [47]. Althoughmutations in these genes are all associatedwith
autosomal recessive inheritance, thegeneencoding theNDUFA1subunit
is onXq24, and the correspondingmutations areX-linked recessive [48].
Abnormalities in structural subunits are often associated with
accumulation of assembly intermediates, and their investigation has
contributed to outlining themain steps of CI biogenesis. An early study,
based on Western blot analysis of patient-derived ﬁbroblast samples
[49], showed different assembly proﬁles according to mutations in
speciﬁc subunits. This observation was later conﬁrmed and reﬁned by
using BNGE [45,50]. For instance, subunits NDUFS2, NDUFS7, and
NDUFS8 are parts of an early peripheral arm subassembly [51], which
explains why their mutations are associated with very low levels of
fully assembled CI [51–53]. Likewise, accumulation of a subassembly
intermediate with a molecular weight ≈ 830kDa is consistently
associated with mutations in NDUFS6, NDUFS1, NDUFS4, and
NDUFV1. These subunits are incorporated late in the assembly
sequence, and all cluster to the tip of the peripheral arm [51], which
can explain why the same assembly defect is common to all of their
mutations [24,54]. The ≈ 830-kDa subassembly intermediate is
enzymatically inactive, but is able to interact with CIII [33,50,54–57].
2.3. Human CI chaperones/assembly factors
Several proteins are involved in the assembly of CI but are not part of
the ﬁnal structure of the enzyme and, therefore, are deﬁned in the strict
sense as CI assembly factors. The homologs of two assembly factors,
CIA30 and CIA84, found in the aerobic fungus N. crassa, have been
identiﬁed in humans [23,58,59]. The role of the CIA84 human homolog
remains to be elucidated. Conversely, RNA interference assays have
shown that NDUFAF1 (the human homolog of CIA30) is necessary for CI
assembly [60], and a mutation in this protein was reported in a patient
with cardiomyoencephalopathy and reduced levels of CI [46]. NDUFAF1/
CIA30 is present in two high-molecular-weight complexes [60] of ≈850
and ≈500kDa [35,61] that do not contain CI subunits, but exhibit someFig. 1. Assembly of the oxidative phosphorylation (OXPHOS) system. Human CI assembly proc
to the pathway proposed for yeast [91]. CIV assembly sequence in human cells [114,123]
assembly factors in which pathological mutations have been found are marked in red. The
Pathological associations between incompletely assembled species are indicated with red achanges in relative proportion and size in patients with mutations in
different nuclear structural subunits [61]. Immunoprecipitation studies
demonstrated a speciﬁc interaction of NDUFAF1/CIA30 with some
mitochondrial and nuclear CI subunits [46]. These data suggest that
NDUFAF1/CIA30 interacts transientlywith CI intermediates but notwith
the fully assembled complex [24].
Through the use of differential genome subtraction to ﬁnd genes
present in aerobic yeasts but missing in fermentative yeasts, a new CI
chaperone (B17.2L) was identiﬁed. This protein is orthologous to the
human B17.2 (NDUFA12) structural subunit. A null mutation of
NDUFA12L was detected in a patient with progressive encephalopathy
and impaired CI assembly [44]. NDUFA12L/B17.2L is associated with
the ≈ 830-kDa CI subassembly intermediate in NDUFV1-, NDUFS4-,
and NDUFS6-deﬁcient patients, but not in controls or in patients who
do not accumulate the ≈830-kDa subcomplex [44,61]. This suggests
that the latter is likely to be a stalled assembly intermediate, rather
than a degradation product [54]. The complete absence of NDUFA12L/
B17.2L does not entirely prevent the formation of fully assembled CI
[44,45], indicating that the role of this protein is to stabilize the
intermediate(s) and to help some, possibly speciﬁc subunits to be
incorporated into the nascent complex.
Very recently, a homozygous mutation in C6ORF66 was associated
with severe CI deﬁciency in ﬁve consanguineous patients presenting
with infantile mitochondrial encephalopathy and in one case of
antenatal cardiomyopathy. BNGE of mutant muscle mitochondria
revealed low levels of fully assembled CI and accumulation of
assembly intermediates that were absent in controls [47].
2.4. The CI assembly model
CI assembly has been extensively studied in the aerobic fungus N.
crassa. In this organism, peripheral and membrane assembly inter-
mediates are constructed independently and are then assembled
together to form mature CI [24,62]. In humans, two models have been
proposed. The ﬁrst model [51] is based on experiments of time course
inhibition of mitochondrial protein synthesis. Similar to what is
observed in N. crassa, the subunits are integrated in two distinct
modules that are preassembled independently and then joined
together in the last step. The ﬁrst structure contains the peripheral
arm subunits, and the second one contains the membrane arm
subunits. The second model is based on subunit analysis of the
subassembly intermediates of patients with different genetic defects
[39]. According to this model, which was later partially conﬁrmed
[54,63], subassemblies of the peripheral and membrane arms come
together before the completion of each arm (Fig. 1). In particular, an
early peripheral arm assembly module (consisting of at least NDUFS2,
NDUFS3, NDUFS7, and NDUFS8) is anchored to the membrane by a
partially assembledmembrane arm that contains some of themtDNA-
encoded subunits (at least ND1) [24]. Subsequently, the membrane
arm is expanded and the assembly is completed with the incorpora-
tion of the last peripheral arm subunits NDUFV1, NDUFV2, NDUFV3,
NDUFV6, NDUFS1, NDUFS4, and NDUFS6. NDUFAF1/CIA30 would act
in the early stages of CI assembly, and NDUFA12L/B17.2L acts to
stabilize the ≈830-kDa subcomplex before the subunit cluster forming
the “tip” of the peripheral arm is added. Then, the NDUFA12L/B17.2L
chaperone is released from the complex [54,61].
3. Complex III
Electrons are funneled to complex III (cytochrome bc1 complex or
ubiquinol:cytochrome c oxidoreductase, CIII) from upstream electroness according to the latest published models [24,54,63]. CIII assembly model by analogy
updated with the latest ﬁndings. Complex V assembly model [146,160]. Subunits and
association of complexes I, III and IV into supercomplexes is also represented [165].
rrows.
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and eventually ubiquinol. CIII works as a tightly associated dimer
embedded in the inner mitochondrial membrane. In mammals, each
monomer is composed of 11 different structural subunits [64,65].
Three subunits contain the metal centers responsible for electron
transfer: cytochrome b (MTCYB), cytochrome c1 (CYC1), and the
Rieske Fe–S protein (UQCRFS1 or RISP). The function of the other eight
subunits remains to be elucidated. MTCYB is encoded by mtDNA,
whereas the remaining subunits are encoded by nuclear genes.
Disorders related to mitochondrial CIII deﬁciency (Table 2) are
clinically heterogeneous and relatively rare [66–68]. Most of the
cases are caused by mutations in the mtDNA-encoded subunit
cytochrome b.
3.1. Mutations in structural subunits
MTCYB mutations are associated with a number of different
clinical presentations including mitochondrial encephalopathy
[69,70], mitochondrial encephalomyopathy [71], cardiomyopathy
[72,73], septo-optic dysplasia [74], and multisystem disorder [75].
However, the majority of patients with these mutations present with
an isolated myopathy with ragged red ﬁbers (RRFs), characterized by
exercise intolerance, weakness, and myoglobinuria [76–81]. Most of
the myopathy-related mutations are sporadic and conﬁned to muscle
[78]. Interestingly, mutations in MTCYB can be associated with
combined CI + CIII deﬁciency [71,78–80], possibly because they
compromise the formation of enzymatically active supercomplexes
(see below).
Only one mutation in a nuclear-encoded CIII structural subunit has
been described so far [82], a homozygous 4-bp deletion in the UQCRB
gene, encoding the ubiquinone-binding protein (subunit VII or QP-C
subunit). The patient, a young girl, exhibited CIII deﬁciency and low
levels of cytochrome b, associated with hypoglycemia and liver
dysfunction.
3.2. Human assembly factor BCS1L
More than 20 pathogenic mutations have been reported in the CIII
assembly factor BCS1L, a member of the AAA+ family of proteins.
BCS1L mutations are associated with a wide variety of phenotypic
manifestations: from multivisceral GRACILE syndrome (growth
retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis,
and early death) [9]; to congenital metabolic acidosis, neonatal
proximal tubulopathy, liver failure, and encephalopathy [6,83,84];Table 2
Online Mendelian Inheritance in Man (OMIM) reference numbers for complex III,
complex IV, and complex V deﬁciency
Clinical phenotype Mutated gene OMIM [25]
Complex III deﬁciency Various 124000
GRACILE syndrome BCS1L 603358
Björnstad syndrome BCS1L 262000
mtDNA-encoded structural subunit MTCYB 516020
CIII assembly factor BCS1L 603647
Complex IV deﬁciency Various 220110
French-Canadian Leigh syndrome (LSFC) LRPPRC 220111
mtDNA-encoded structural subunits MTCO1 516030
MTCO2 516040
MTCO3 516050
CIV assembly factors SURF1 185620
COX10 602125
COX15 603646
SCO1 603644
SCO2 604272
LRPPRC 607544
NARP MTATP6 551500
mtDNA-encoded structural subunit MTATP6 516060isolated mitochondrial encephalopathy [85]; or milder Björnstad
syndrome (sensorineural hearing loss and pili torti) [86]. All patients
with BCS1L mutations exhibited decreased CIII activity, except for the
patients with GRACILE. GRACILE segregates with a commonmutation,
S78G, which is of Finnish disease heritage [6]. Different clinical
presentations are likely related to mutations in speciﬁc BCS1L
functional domains. For instance, a severe phenotype is predicted
when the ATP binding or ATP hydrolysis domain is involved [86].
BCS1L is part of two, sometimes three, electrophoretically distinct
high-molecular-weight species that do not include any CIII subunit
[85]. Their number depends on the conditions used for sample
preparation [85,86] (see Fig. 2). Their composition is unknown, but
BCS1L is likely to form homomers, most probably ring-shaped
hexamers, as other AAA+ proteins do [87]. In S. cerevisiae, Bcs1p was
demonstrated to interact with cytochrome bc1, but, as in humans, a
substantial fraction of the protein was shown to be present in a high-
molecular-weight complex in which no CIII subunits were detected
[88]. These ﬁndings suggest that the interaction of human BCS1L and
its yeast homologwith CIII components is transient. However, physical
association between Bcs1p and the CIII dimer has recently been
reported in digitonin-solubilized yeast mitochondria [89]. These
results were not conﬁrmed by us in human samples (Fig. 2A). These
different results could be due to differences in extraction and/or
solubilization of mitochondrial membranes [85,88].
3.3. The CIII assembly process
Despite the fact that mammalian CIII contains an additional
subunit (subunit 9) comparedwith S. cerevisiae CIII [90], the structural
similarity between the yeast and mammalian enzymes has made the
former a useful paradigm with which to understand the assembly
process of the latter. In yeast, the assembly of CIII is a dynamic,
stepwise process that starts with the formation of three different
subcomplexes: cytochrome b + Qcr7p and Qcr8p; cytochrome c1 +
Qcr6p and Qcr9p; and the core protein subcomplex composed of the
Core1 and Core2 proteins. These subcomplexes assemble together to
form a cytochrome bc1 precomplex to which the Rieske Fe–S (RISP)
and Qcr10p subunit are eventually added [88,91]. Yeast Bcs1p,
orthologous to human BCS1L, is essential for the insertion of RISP
into nascent CIII and, consequently, for CIII complete assembly and
activity [88,92]. Bcs1p has been proposed to act as an ATP-dependent
chaperone that, by physically interacting with yeast pre-CIII, main-
tains it in a competent state for the incorporation of RISP. CIII assembly
is then completed by addition of the smallest subunit Qcr10p [88]. In
humans as in yeast, BCS1L intervenes in the ﬁnal steps of CIII assembly
by promoting the incorporation of RISP into the precomplex [85].
BCS1L-deﬁcient patient cells exhibit very low RISP incorporation, thus
determining the formation of a catalytically inactive, structurally
unstable dimeric pre-CIII. Incidentally, these observations indicate
that in both organisms, dimerization of the complex occurs before full
assembly of CIII monomer has been completed (Fig. 1). However,
several details are missing, including the sequence of incorporation of
both the protein subunits and the prosthetic groups, the formation of
the CIII dimmer, and the mechanism of BCS1L–RISP interaction.
4. Complex IV
Cytochrome c oxidase (COX, complex IV, CIV), the terminal enzyme
of the mitochondrial respiratory chain, catalyzes the electron transfer
from reduced cytochrome c to molecular oxygen. According to the
structure of the bovine enzyme, mammalian CIV is a heteromeric
complex composed of 13 different subunits [93,94]. The catalytic core
of the enzyme is composed of mtDNA-encoded subunits MTCO1 and
MTCO2, which contain the two heme A moieties (a and a3) and the
two copper centers (CuA and CuB) responsible for the electron transfer.
A third mtDNA-encoded subunit (MTCO3) is part of the structural core
Fig. 2. Studies of the BCS1L complex. (A) Mitochondrial fractions from 143B cells and the mtDNA-less ρ0 derivatives were solubilized for BNGE analysis using either 1% (w/v ﬁnal
concentration) docecylmaltoside (DDM) or 1% (w/v ﬁnal concentration) digitonin (Dig). The same blot was sequentially immunostained with monoclonal antibodies against the
Core2 (UQCRC2) complex III structural subunit (Molecular Probes) and BCS1L (Novus Biologicals) and polyclonal antibodies against BCS1L (Proteintech). Even in digitonin-solubilized
samples no interaction between BCS1L and complex III is observed. Formation of the high-molecular-weight complex in which BCS1L is found is independent of CIII assembly as it is
also present in ρ0 cells. (B) The same three complexes in digitonin-solubilized cultured ﬁbroblast samples are found in a control and in Patient 2 (compound heterozygote for the
BCS1L mutations R183C/R184C [85]). For complex nomenclature, see Ref. [86].
Fig. 3.Diverse patterns of anomalous COX assembly of different genetic nature. (See text
for details.)
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(COX4, COX5A, COX5B, COX6A, COX6B, COX6C, COX7A, COX7B, COX7C
and COX8) are encoded in the nuclear DNA and must be imported,
processed, and assembled together with the mtDNA-encoded sub-
units. The function of the nuclear-encoded subunits is currently
unknown, but they plausibly have regulatory [95] and stabilization
roles. In humans, for COX6A and COX7A there are different tissue-
speciﬁc isoforms: the heart (H) type, which is present in skeletal and
cardiac muscle, and the liver (L) type, which is present in extra-muscle
tissues [96]. A testis-speciﬁc COX6B2 isoform and a lung-speciﬁc COX4
have also been identiﬁed, revealing the striking functional plasticity of
the enzyme.
COX deﬁciency is one of the most common respiratory chain
defects in human pathology, and it is associated with different clinical
phenotypes with heterogeneous genetic causes.
4.1. Mutations in CIV structural subunits
Rare disease-related mutations have been described in the three
mtDNA-encoded COX subunits (Table 2), all of them affecting the
assembly/stability of CIV [97–99]. Mutations have been associated
with a range of phenotypes including pure myopathy, MELAS,
encephalomyopathy, and a motor neuron disease-like presentation
[100].
Mutations in nuclear-encoded COX structural subunits have been
searched for on several occasions but none hasbeen found [101–104],
raising the conjecture that they are incompatible with extrauterine
life. However, we recently characterized a pathogenic mutation of
the COX6B1 ubiquitously expressed subunit in two cases of
mitochondrial encephalomyopathy and isolated COX deﬁciency
(article in preparation).
4.2. Human complex IV assembly factors
In S. cerevisiae, CIV biogenesis requires the action of ≈20 nuclear-
encoded accessory proteins that are involved in speciﬁc stages of
the assembly process [105]. More than half of these proteins have
known human orthologs [100,106]. Autosomal recessive CIV
deﬁciency has been associated with mutations in several such
genes (Table 2). By deﬁnition, the corresponding proteins are all
involved in the biogenesis of CIV but are not part of the mature
enzyme.
4.2.1. Surf1
SURF1 is a 30-kDa protein composed of two transmembrane
domains at the N and C termini, connecting an intermediate, relatively
hydrophilic region that loops out into the intermembrane space. More
than 40 different pathogenic mutations have been reported in theSURF1 gene [107,108], all causing a speciﬁc clinical presentation, Leigh
syndrome with COX deﬁciency (LSCOX) [109,110]. This consistency can
be explained by the observation that all the mutations of SURF1
reported to date determine the absence of the corresponding protein.
This is, in turn, associated with marked reduction in the amount of
fully assembled COX and accumulation of subassembly intermediates
S1 (MTCO1) and S2 (MTCO1–COX4–COX5A) [111–113] (Figs. 1 and 3).
Although the mechanistic function of the SURF1 protein is still
unclear, the accumulation of S1 and S2 subassemblies indicates a role
for this protein in the early stages of CIV assembly, most likely before
the incorporation of MTCO2 into the S2 assembly intermediate [114].
SURF1 orthologs are present in terminal oxidase operons of several
prokaryotes inwhich COX is composed of only the three core subunits.
This observation suggests a role for SURF1 in the formation of the
catalytic centers [115], for instance, in the insertion of heme A into the
a3 center or in the stabilization of the a3–CuB binuclear center [116]. In
SURF1 null-mutant human samples [109], as well as in yeast strains
lacking the SURF1 homolog (SHY1) [117,118], fully assembled,
functionally active CIV is found in residual amounts, suggesting
partial functional redundancy. Yeast Shy1p has been detected in
several high-molecular-weight complexes, some of which contain CIV
subunits. This suggests that Shy1 takes part in several steps of COX
assembly and, possibly, in the formation of CIV+CIII supercomplexes
as well [119]. However, SURF1 and Shy1 do not complement each
other's defects, indicating functional divergence during evolution.
SURF1-deﬁcient recombinant animals have been generated, including
knockout mouse and knockdown ﬂy and ﬁsh models [7,120–122]. Not
only did the mouse model display no neurological symptoms, but
rather, it exhibited resistance to calcium-dependent excitotoxic brain
damage and increased longevity, suggesting that moderate reduction
of respiratory chain activity may prolong life span, at least under
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laboratory mice are maintained. Constitutive knockdown of Surf1
expression in Drosophila melanogaster [121] and in Dario rerio
zebraﬁsh [122] produced COX deﬁciency associated with develop-
mental impairment and nervous system involvement. However, pan-
neuronal knockdown in D. melanogaster was associated with
increased lifetime, again suggesting a direct relationship between
longevity and (partial) impairment of cellular respiration.
4.2.2. COX10 and COX15
Heme A is an essential component of the catalytic centers of CIV. It
is a unique heme derivative found in all eukaryotic and some
prokaryotic COX species [123]. COX10 and COX15 are two enzymes
involved in the terminal steps of the heme A biosynthetic pathway
[124–126] that have been associated with exceptionally rare clinical
phenotypes in humans. Mutations in COX10 can determine leukody-
strophy and renal tubulopathy [127], Leigh syndrome, or fatal infantile
hypertrophic cardiomyopathy [128,129]. Mutations in COX15 may
cause fatal infantile hypertrophic cardiomyopathy [130] or Leigh
syndrome [131,132]. Total heme A content is reduced in both
conditions [128,130]. In COX10- or COX15-deﬁcient human cells
[112,128,129] and COX10 knockout murine skeletal muscle [133],
COX holoenzyme is very low, with no assembly intermediates [130]
(Fig. 3).
4.2.3. SCO1 and SCO2
SCO1 and SCO2 are paralog genes encoding two metallochaper-
ones responsible, together with other factors, such as COX17, for the
insertion of copper in the COX catalytic center. Mutations in SCO1
or SCO2 have been associated with neonatal hepatopathy and
ketoacidotic coma (SCO1) or infantile cardiomyopathy (SCO2), both
characterized by profound COX deﬁciency [134–136]. Unlike the two
yeast Sco proteins, which seem to have partially redundant
functions, human SCO1 and SCO2 have non-overlapping cooperative
roles in copper delivery to the CuA site in the MTCO2 subunit [137].
Copper insertion is required for the maturation of both MTCO1 and
MTCO2 (reviewed in Ref. [138]). In SCO1- and SCO2-deﬁcient cells
fully assembled COX is reduced [113,138], whereas COX subassem-
blies containing MTCO1, COX4, and COX5A accumulate [112,113,138].
According to the current model of COX assembly, these results
suggest that formation of copper centers is required for MTCO2 to
be incorporated into nascent COX (Fig. 3). In addition, SCO1 and
SCO2 play a role in general copper homeostasis [8] and in
regulation of OXPHOS activity in human cells. For instance, SCO2
expression is regulated by p53, and p53-mediated downregulation
of SCO2 levels is proposed to determine the shift from respiration to
glycolysis (the so-called Warburg phenomenon) observed in tumor
cells [139].
4.2.4. Lrpprc
COX-defective French-Canadian Leigh syndrome (LSFC) is caused
by mutations in LRPPRC [140], a factor involved in the stabilization of
MTCO1 and MTCO3 messenger RNAs [140,141].
4.3. The CIV assembly pathway
CIV assembly has been studied in human cells [114] using
translational inhibitors and metabolic labeling, in combination with
two-dimension BNGE, and further reﬁned by studies on COX-defective
cells (Fig. 1) [112,113] (reviewed in Ref. [123]).
The ﬁrst step of COX assembly is the insertion of MTCO1 into the
inner mitochondrial membrane (assembly intermediate S1), followed
by the incorporation of subunits COX4 and COX5A (assembly
intermediate S2). As COX10 and COX15 mutant cells do not
accumulate S2 intermediates, heme A is likely required for the
formation of such subcomplexes [112,128,130]. Therefore, heme Ainsertion is likely to occur just after MTCO1 insertion (S1) or during
the formation of the S2 subassembly. The insertion of CuB and
insertion of heme a3 are likely to occur together, prior to
incorporation of MTCO2 into the nascent complex [123]. It is not
clear whether CuA is inserted into S1 or S2 intermediates [137].
However, the absence of MTCO2 in the subcomplexes that
accumulate in SCO1 and SCO2 mutant cells indicates that matura-
tion of the CuA center is necessary for the addition of MTCO2 to the
S2 intermediate [112,113,138]. SURF1 is believed to play a role in this
step. Incorporation of MTCO2 is followed by cascade-like, rapid
incorporation of most of the remaining COX subunits, to produce S3,
a quasi-complete assembly intermediate (also named subcomplex b
[112,113]). The formation of S3 from S2 is initiated by the insertion
of MTCO3, as indicated by the absence of completely assembled COX
and accumulation of a MTCO1–COX4–COX5A–MTCO2 subcomplex in
human MTCO3-lacking mutant cells [105] (Fig. 3). Finally, the
assembly of the monomeric holocomplex (S4) is completed by the
addition of a few additional subunits (Fig. 1), including COX6A,
COX7A, or COX7B [114] and, according to our own data, COX6B as
well (article in preparation). The dimerization of COX is thought to
occur thereafter [142].
5. Complex V
Mitochondrial ATP synthase or complex V (CV) exploits the energy
obtained by the protons accumulated in the intermembrane space
ﬂowing back to the mitochondrial matrix to promote the condensa-
tion of ADP and inorganic phosphate into ATP. Mammalian CV is a
multisubunit complex consisting of two functional modules, the
hydrophilic, matrix-facing F1, and hydrophobic, membrane-
embedded F0, particles. F1 and F0 are physically connected to each
other by two protein stalks. The F1 particle contains ﬁve different
subunits (3α, 3β, γ, δ, and ɛ), and acts as the catalytic ATP synthase
domain. The F0 particle consists of eight subunits (a, b, c, d, e, f, g, and
A6L). The central stalk contains a subset of F1 subunits (γ, δ, and ɛ), and
the peripheral stalk or stator is composed of the OSCP, F6, b, and d
subunits [143–145]. F0 subunits a and A6L are encoded by the MTATP6
and MTATP8 mtDNA genes, respectively.
CV deﬁciency is rare and mutations are concentrated mainly in the
mitochondrial MTATP6 gene (Table 2).
5.1. Structural subunit mutations
Transversion 8993TNG and transition 8993TNC in the MTATP6
gene are the most frequent mutations of CV in humans, and
depending on mutation load, they may lead to adult-onset, slowly
progressive NARP (neuropathy, ataxia, and retinitis pigmentosa) or to
severe infantile MILS (maternally inherited Leigh syndrome) [146].
Another very rare MTATP6 gene mutation is a 2-bp microdeletion of
positions 9205 and 9206 (ΔTA9205) that was discovered in a
newborn with transient lactic acidosis [147] and in a child with
severe encephalopathy and hyperlactic acidemia [148]. This mutation
abolishes both the MTATP6 STOP codon and the cleavage site
between the MTATP6 and MTCO3 genes, thus producing combined
defects of CV and CIV [148]. There are contradictory observations
about the molecular consequences of the mutations in MTATP6. In
one study, BNGE showed severe reduction of fully assembled CV and
accumulation of several lower-molecular-weight subcomplexes
[148–150]. However, another study found that in T8993C or
T8993G mutant cells, it maintains its structural integrity [151],
suggesting catalytic rather than structural impairment of mutant CV.
Recently, a nonsense mutation in MTATP8 has been reported in a
patient with hypertrophic cardiomyopathy and neuropathy [152].
This mutation is associated with decreased CV activity, decreased
levels of fully assembled ATP synthase, and accumulation of
subcomplexes [150].
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Among the several factors known to be necessary for CV assembly
in yeast, only two (ATP11 and ATP12) have been identiﬁed in humans
and proven to be functionally active [153–155]. In S. cerevisiae, Atp11p
and Atp12p promote assembly of the F1 particle by binding to the β
and α subunits, respectively, thus preventing the formation of large,
nonfunctional α and β subunit aggregates [156–158]. In mammalian
cells, no speciﬁc factors in F0 assembly have been identiﬁed yet [146].
However, a protein homolog of yeast ATP23 is present in humans that
could retain the function demonstrated for this factor in the assembly
of F0 in S. cerevisiae [159].
A homozygous missense mutation in the human ATP12 homolog
has been reported in a CV-deﬁcient patient presenting with early-
onset severe lactic acidosis, hypertrophic cardiomyopathy, and
methylglutaconic aciduria [153]. The amount of ATP synthase was
low, but no subassembly intermediates were detected, possibly
because ATP12 acts in the very early steps of F1 assembly [160].
Several other CV-defective cases have also been described, but their
genetic cause remains unknown [154].
5.3. The CV assembly process
A CV assembly model has been outlined in mammalian cells on the
basis of a combination of pulse–chase protein labeling and two-
dimensional BNGE experiments [161] (Fig. 1). Assembly starts with
formation of the F1 particle, carried out by the speciﬁc assembly
factors ATP11 and ATP12 [162]. The F1 particle then directs the
sequential assembly of F0. In particular, F1 interacts with the c
subunits; this step is followed by incorporation of other subunits,
including b, OSCP, and F6, forming the assembly intermediate called
V⁎. Incorporation of mtDNA-encoded subunits a and A6L occurs in the
ﬁnal step. This sequence and the essential role of the mtDNA-encoded
subunits to complete the assembly are conﬁrmed by the fact that the
V⁎ intermediate and lower-order subassemblies are accumulated in
mutant MTATP6 or MTATP8 CV species (see above), or when
mitochondrial protein synthesis is inhibited [160], and in mtDNA-
less ρ0 cells [163]. Further steps in mammalian ATP synthase
biogenesis include generation of dimers, with the aid of subunits e
and g [9], and of higher-order oligomers (V1–V4) [164].
6. Supercomplexes
The respiratory chain is organized, at least in part, as supramole-
cular associations inwhich the individual complexes of the respiratory
chain interact with each other, giving rise to so-called respirasomes
[12]. In mammalian mitochondria, almost all CI is assembled into
supercomplexes containing monomeric CI, dimeric CIII, and up to four
COX complexes (I1III2IV0–4). By the use of digitonin solubilization of
isolated mitochondria from bovine heart and BNGE, a I1III2IV1
supercomplex has been isolated and its three-dimensional structure
has been determined by electronmicroscopy [165,166]. The functional
relevance of these supercomplexes has not been fully proven yet.
However, supercomplex assembly is very likely to be a step necessary
for respiratory activity, as the ability to form sufﬁcient levels of
respirasomes sets the threshold for functional complementation in
hybrid cells generated by fusing CIII- and CIV-deﬁcient cell lines [167].
Furthermore, destabilization of the respiratory chain supercomplexes
in cardiolipin-deﬁcient mitochondria seems to be the cause of Barth
syndrome [168]. Cardiolipin is needed for stabilization of the super-
complexes [169].
The association into respirasomes is essential for the stability of CI,
demonstrated by the fact that CI is absent in MTCYB mutant cells that
are not able to assemble CIII [170,171] and in cells with impaired
assembly of CIV [172,173]. This has important implications for human
pathology, because mutations that do not allow the formation of CIIIresult in an impairment of CI assembly/stability and manifest as a
combined CI+ III defect (see above and Refs. [71,78–80]). The idea that
CIII and CI interact is further supported by the observation that
patients carrying mutations in the NDUFS4 CI subunit also display
reduced CIII activity [50]. Even incompletely assembled CI and CIII can
associate and form supercomplexes, as has, in fact, been observed in
some pathological cases. The ≈830-kDa CI assembly intermediate can
interact with CIII [44,54]. Likewise, the nonfunctional, UQCRFS1-less
pre-CIII2 of BCS1L mutant cells is able to associate with CIV and CI
[85,86]. This is consistent with the observation that it is the physical
presence and not the activity of CIII that is required for stabilization of
CI [170]. Therefore, the presence of an incomplete pre-CIII2 is enough
to guarantee the proper assembly of CI. This explains why patients
with mutations in BCS1L present with an isolated CIII defect.
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